Publications: 

2022-Onwards 

1. Hirani R, Nandakumar S, Zaman N, Prabhakaraalva P, King SA, Kalidindi TM, Ghale R, Rajanala SH, Fidele DC, De Stanchina E, Mary Lee GS, Taplin ME, Balk SP, Sowalsky AG, Morris MJ, Kishore Pillarsetty NV, Stopsack KH, Gopalan A, Mucci LA, Kyprianou N, Tewari AK, Danila D, Kantoff PW, Chakraborty G*. BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways. Cell Rep. 2025 May 30;44(6):115779. PMID: 40448998 DOI:  10.1016/j.celrep.2025.115779 
2. Zaman N, Kushwah AK, Badriprasad A, Chakraborty G*. Unravelling the Molecular Basis of PARP Inhibitor Resistance in Prostate Cancer with Homologous Recombination Repair Deficiency. Int Rev Cell Mol Biol. 2024;389:257-301. PMID: 39396849 DOI: 10.1016/bs.ircmb.2024.03.004
3. Rajanala SA*, Ghale R, Nandakumar S, Chadalavada K, Lee GSM, Stopsack KH,  Chen Y,. Nanjangud GJ,  Chakraborty G*, Kantoff PW*. Quantifying Y Chromosome Loss in Primary and Metastatic Prostate Cancer by Chromosome Painting, PLoS One. 2024 Apr 29;19(4):e0301989. doi: 10.1371/journal.pone.0301989. PMID: 38683764.   DOI: 10.1371/journal.pone.0301989
4. Rajanala SH, Plym A, Vaselkiv JB, Ebot EM, Matsoukas K, Lin Z, Chakraborty G, Markt SC, Penney KL, Lee GM, Mucci LA, Kantoff PW, Stopsack KH. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis. Carcinogenesis. 2024 Feb 12;45(1-2):35-44. DOI: 10.1093/carcin/bgad075
5. Chakraborty G, Gupta K, Kyprianou N. Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer. Nature Communications, 2023;14:567. DOI: 10.1038/s41467-023-36253-1
6. Yoshikawa Y, Stopsack KH, Wang XV, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S, Lee GM, Frank D, Davicioni E, Liu G, Carducci MA, Azuma H, Kantoff PW, Sweeney CJ. Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. Mol Oncol. 2022 Dec;16(22):3994-4010. DOI: 10.1002/1878-0261.13314
7. Korsen JA, Kalidindi TM, Khitrov S, Samuels ZV, Chakraborty G, Gutierrez JA, Poirier JT, Rudin CM, Chen Y, Morris MJ, Pillarsetty N, Lewis JS. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. J Nucl Med. 2022 Sep;63(9):1401-1407. DOI: 10.2967/jnumed.121.263221
8. Chakraborty G*, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee GM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, Mucci LA, Wibmer AG, Schultz N*, Kantoff PW*. The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. Clin Cancer Res. 2022 Aug 15;28(16):3603-3617. DOI: 10.1158/1078-0432.CCR-21-4272
9. Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, Kumar D, Caggiano EG, Capogiri M, Zhang B, Ji Y, Maity SN, Hu M, Bai S, Aparicio AM, Efstathiou E, Logothetis CJ, Navin N, Navone NM, Chen Y, Giancotti FG. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022 Apr 5;39(1): DOI: 10.1016/j.celrep.2022.110595
10. Mazzu YZ, Liao YR, Nandakumar S, Jehane LE, Koche RP, Rajanala SH, Li R, Zhao H, Gerke TA, Chakraborty G, Lee GM, Nanjangud GJ, Gopalan A, Chen Y, Kantoff PW. Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. Oncogene. 2022 Jan;41(5):671-682. DOI: 10.1038/s41388-021-02118-4

Publications Highlight Before 2022

1. Chakraborty G*, Patail NK, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq M, Jehane LE, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila D, Kantoff PW*. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. Clin Cancer Res. 2021 Mar 15;27(6):1792-1806.  DOI: 10.1158/1078-0432.CCR-20-2483.
2. Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R, Chadalavada K, Yoshikawa Y, Khan NA, Chen Y, Abida W, Mucci LA, Lee GM, Nanjangud GJ, Kantoff PW. Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clin Cancer Res. 2020 Apr 15;26(8):2047-2064. DOI: 10.1158/1078-0432.CCR-19-1570.
3. Su W, Han HH, Wang Y, Zhang B, Zhou B, Cheng Y, Rumandla A, Gurrapu S, Chakraborty G, Su J, Yang G, Liang X, Wang G, Rosen N, Scher HI, Ouerfelli O, Giancotti FG. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell. 2019 Aug 12;36(2):139-155.  DOI: 10.1016/j.ccell.2019.06.009
4. Gadiya M, Chakraborty G*. Signaling by discoidin domain receptor 1 in cancer metastasis. Cell Adh Migr. 2018;12(4):315-323. DOI: 10.1080/19336918.2018.1520556
5. Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest. 2018 Jul 2;128(7):2979-2995. DOI: 10.1172/JCI96769
6. Gao H^#, Chakraborty G^#,  Zhang Z, Akalay I, Gadiya M, Gao Y, Sinha S, Hu J, Jiang C, Akram M, Brogi E, Leitinger B, Giancotti FG. Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell. 2016 Jun 30;166(1):47-62. DOI: 10.1016/j.cell.2016.06.009
7. Gao H, Chakraborty G, Lee-Lim AP, Mavrakis KJ, Wendel HG, Giancotti FG. Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16532-7. DOI: 10.1073/pnas.1403234111
8. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012 Aug 17;150(4):764-79. DOI: 10.1016/j.cell.2012.06.035
9. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008 Jan 1;68(1):152-61. DOI: 10.1158/0008-5472.CAN-07-2126
10. Chakraborty G, Rangaswami H, Jain S, Kundu GC. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem. 2006 Apr 21;281(16):11322-31. DOI: 10.1074/jbc.M512546200

Complete List of the Published Work in MyBibliography:

https://www.ncbi.nlm.nih.gov/myncbi/goutam.chakraborty.1/bibliography/public/

• *Corresponding Author 

# Co First Author